Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Post by Trogarzonon Aug 07, 2023 11:13am
122 Views
Post# 35576152

Deal or no deal

Deal or no dealThey have until Oct 31 to find the cash to satisfy Marathon. Tree ways, 1. Sign a deal with upfronf cash.  Well I think a negociating partner would'nt rush into a deal knowing that the seller needs cash  very badly. 2. Do a financing at 50 cents.  Well to get like 25M they need to dilute like 60% de float.  3. Cutting expenses. Well that takes time and actually raise expenses in the sorth term because of severance cost and other related cost.  So a hugely dilute cash raise seems the most probable issue and that's why we stand at 48 cents.  The company want to continue existing but shareholders will be diluted beyond possibility of recouping anyhing short from a cure to cancer.  And that cure ain't happening before the Oct 31 deadline nad the actual chance of it working are like a coin toss at the moment. Oh yes it can work but that's a big if at the moment.  They are looking after themseves with huge bonuses and option packages on what basis exactly.  It makes it look like the only ones they are looking after are themselves and that's becoming apparent now.  Anyway they have no choice because in less than 3 months it's going to be Marathon's pipeline.  
<< Previous
Bullboard Posts
Next >>